3 min read
Key Strategies for Overcoming Data Analysis Difficulties During NDA/MAA Submissions
When database locks are delayed, or regulatory agencies request additional analyses for new drug applications (NDAs) or marketing authorization applications (MAAs), it seems there is no alternative but to take a hit to the timeline — or is there?